← Back to Home

Activating Immune Attacks Within Tumors: Vir and Gilead Partner to Develop Dual-Masked Therapies

Three solid-tumor drug candidates will combine protein engineering with cleavable molecular masks. The partnership has a potential total value of approximately $1.88 billion, but most payments depend on development outcomes, and the new drugs’ safety and efficacy remain to be validated.

By SURL BioNews

Directing T cells toward cancer cells is one approach to cancer immunotherapy; concentrating the attack within tumors while reducing effects on other tissues is a key development challenge. Vir Biotechnology and Gilead Sciences announced a partnership on October 14 to develop three dual-masked T-cell engagers for solid tumors, seeking to use cleavable molecular masks to control where the drugs become active.

The agreement was signed on October 9. Vir is responsible for early discovery, design and optimization, using protein engineering, PRO-XTEN masking technology and the dAIsY artificial intelligence platform to create candidate molecules. Gilead receives an exclusive license to select drug candidates and take over subsequent development, manufacturing and commercialization. Neither company has disclosed the specific tumor antigens targeted by the three drugs.

T-cell engagers bring immune cells and cancer cells into proximity to facilitate a killing response. According to Vir’s technical description, PRO-XTEN is designed to keep drugs at low activity while masked, then release their activity after proteases in the tumor microenvironment cleave off the masks. The design also aims to extend the time the molecules remain in the body. Whether this can widen the window between effective and toxic doses still requires validation for each candidate.

AI’s role in the partnership primarily involves optimizing multiple properties of candidate proteins. Vir says dAIsY can assist in designing and screening T-cell engagers, but the announcement did not provide training data, comparative testing or predictive performance for these three programs. AI’s actual contribution to development efficiency and success rates therefore cannot yet be quantified.

The transaction’s value also needs to be understood in its separate components. According to the company announcement and Reuters reporting, Vir may receive $90 million in upfront consideration, comprising $65 million in cash and a $25 million equity investment; up to $45 million in near-term preclinical milestone payments; and up to $1.74 billion in subsequent development, regulatory and commercial milestone payments. Most of the potential total of approximately $1.88 billion depends on future progress and will not all be received upon signing. If products reach the market, Vir may also receive tiered royalties on sales.

Vir’s Form 8-K filing with the U.S. Securities and Exchange Commission further states that Gilead agreed to purchase 1,765,486 shares of Vir stock at $14.16 per share, for a total of approximately $25 million, subject to customary closing conditions. This equity investment is already included in the $90 million described above and should not be counted again.

The agreement establishes a division of responsibilities for taking three early-stage programs from molecular design into subsequent development, but it has not yet produced evidence of the new drug candidates’ efficacy in humans. The central question ahead is whether the masks can effectively limit activity outside tumors in the human body while preserving sufficient anticancer activity. The deal’s scale reflects the two companies’ willingness to invest in the technology; its clinical value remains a question for trials to answer.

References

  1. Vir Biotechnology
  2. Vir Biotechnology / U.S. Securities and Exchange Commission
  3. Reuters via KSL.com